Our Chairman and co-CEO Helmy Eltoukhy joined @CNBC this morning to discuss how blood-based testing can help physicians identify molecular resistance in metastatic #BreastCancer—moving cancer care from one step behind to one step ahead.

“Every great advancement in medicine has come from seeing something that was once invisible.” @Helmy_L2K, CEO of @GuardantHealth, joined me at @spc to talk about the journey from liquid biopsy to early cancer detection, what makes diagnostics such a difficult business, and how AI could help unlock new applications far beyond cancer.

We’re proud to sponsor the 2026 @NCQA Health Innovation Summit in Atlanta. We look forward to connecting with leaders advancing quality, digital transformation, and innovation across healthcare, and discussing how blood-based #ColorectalCancer screening can accelerate adoption and reduce barriers in population health strategies. #NCQASummit

#NewResearch in @JCOPO_ASCO highlights the prognostic value of tissue-free MRD testing. In an analysis of samples from the SUCCESS-A trial, Guardant Reveal® detected molecular residual disease approximately two years after adjuvant chemotherapy, with ctDNA positivity strongly associated with later distant recurrence. Read more: bit.ly/4gY28pT

#Coverage for the Shield™ blood test for #ColorectalCancer screening continues to expand. Starting January 1, 2027, @evicorehc —the second-largest national medical benefit manager in the U.S.—will cover Shield for eligible policyholders, bringing Shield coverage to approximately 94 million Americans ages 45 and older. Details: bit.ly/4htyw3J

How can a blood test help clinicians monitor changes in cancer? On @CNN's The Situation Room this morning, our Chairman and co-CEO Helmy Eltoukhy joined @PamelaBrownCNN to discuss the first-of-its-kind FDA approval of Guardant360® CDx as a companion diagnostic for AstraZeneca’s ETCAMAH™—and its potential to advance more precise, proactive cancer care for certain patients with advanced #BreastCancer. Watch the full segment: bit.ly/4gU5JVN

With more screening options, we can reach the 54 million people who have forgone or delayed their critical #ColorectalCancer screening. Listen below to hear from our Co-CEO AmirAli Talasaz on how blood-based screening options like Shield™ have been proven to help close CRC screening gaps:

We’re heading to Seoul this week for #WCLC26, hosted by @IASLC Together with our research collaborators, we’ll present 20 abstracts highlighting advances in liquid biopsy across #LungCancer, including tissue-free MRD surveillance, treatment-response and resistance research, and investigational early-detection. Details: bit.ly/3SQYODJ

Today, the FDA approved Guardant360® CDx as a companion diagnostic for @AstraZeneca's ETCAMAH™ (camizestrant) in advanced #BreastCancer, representing a major shift toward adaptive cancer management and earlier interception of disease progression based on a blood test. “This approval represents a fundamental shift in how we can stay ahead of breast cancer," added our Chairman and co-CEO Helmy Eltoukhy. "For decades, doctors have largely waited for a scan to show that a tumor has grown before changing treatment. Now, a simple blood test can detect the molecular signs that a cancer is beginning to escape treatment, months before that progression may be visible on a scan, giving doctors an opportunity to switch therapy while the disease is still under control." Details: bit.ly/4qZZVxA

#Innovation matters most when it makes a difference for patients. @BusinessInsider has named us one of America’s Most Innovative Businesses for 2027 with a five-star rating awarded to only 10 companies in the biotechnology category, reflecting the innovative science and technology driving our work across #CancerCare. Recognition marks a moment. Innovation is about what comes next. Details: bit.ly/4hbFave

Behind every life lost to #ColorectalCancer is a story, a family, & a legacy that lives on. Our co-CEO AmirAli Talasaz reflects on the lives and legacies of those who have passed from colorectal cancer & how their stories reinforce the importance of raising awareness, expanding screening options, & continuing the work to change the future of colorectal cancer.

Access to blood-based #ColorectalCancer screening is taking another major step forward. Carelon Healthcare Services, the largest national medical benefit manager in the U.S., will expand coverage of our FDA-approved Shield™ blood test to eligible policyholders beginning November 15. With this update, approximately 90 million people ages 45 and older will have coverage for Shield, representing the vast majority of patients eligible for colorectal cancer screening in the U.S. Details: bit.ly/4x5PREl

#NewResearch published in @JAMAOnc provides additional clinical evidence for Guardant Reveal® for detecting recurrence in early-stage triple-negative #BreastCancer (TNBC). These results further support the potential of ctDNA to detect signs of recurrence earlier and provide meaningful insights after treatment, while strengthening Guardant's body of clinical evidence for molecular diagnostic services. Full pub: bit.ly/45VZyKy

#Care is at the heart of everything we do. We’re honored to share that we’ve been named to @people's 2026 Companies That Care list for the first time. Developed in partnership with @GPTW_US , the list honors companies that demonstrate genuine care for their people, customers, & communities. This recognition is a testament to our people and the care they bring to everything we do, from supporting one another to serving patients. Explore this recognition: bit.ly/4zk3D94

See PEOPLE’s 100 Companies That Care List 2026 people.com/100-companies-tha…

“The first genome was sequenced for $3 billion. You can now sequence a genome for $100." At Global Conference 2026, our “The Next Wave of Health Innovation" panelists highlighted the innovations poised to define the next decade of opportunity across the health ecosystem, and what will be needed to foster them. Watch the replay: milkeninstitute.org/content-… #MIGlobal #GlobalConference #Health #Research #Leadership

As AI reshapes healthcare, data is unlocking what's possible. Following our second-quarter 2026 earnings announcement, our Chairman and co-CEO, Helmy Eltoukhy, joined @FoxBusiness today to discuss the role of AI in advancing blood-based testing and the future of precision medicine. Watch the full conversation: bit.ly/4vWHD13

Today, we reported our second quarter 2026 financial results, with 44% year-over-year revenue growth driven by continued momentum across our Oncology, Screening, and Biopharma & Data businesses. We also increased our full-year 2026 revenue guidance by $40 million to $1.35 billion, representing growth of 36–38%. More details: bit.ly/4h7Gr79